The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers. The world's largest and longest ...

A phase 3 randomized controlled trial found no significant improvements with the GLP-1 exenatide in this population. Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo ...

A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of Ozempic, showed absolutely no benefit or slowing of the course of the degenerative disease after 96 ...

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Poor mental health triggered by alcohol and social media Severe diabetes complication associated with poor mental health Poor mental health triggered by alcohol and social media Daily activities and ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity. HealthDay News — The glucagon-like peptide-1 receptor agonist exenatide ...

FRIDAY, Feb. 7, 2025 (HealthDay News) -- The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity, according to a study published ...

(HealthDay News) — The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson’s disease severity, according to a study published online Feb. 4 in The ...